SERENA-6: Early Camizestrant Switch Improves QoL and Delays Chemotherapy

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, updated results from the Phase III SERENA-6 trial highlighted a significant shift toward precision prophylaxis in the management of hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC).

For oncology nurses, the most compelling data involves the trial's success in maintaining patient quality of life (QoL) and delaying the transition to more toxic chemotherapy or antibody-drug conjugates (ADCs).

Proactive intervention via liquid biopsy

The SERENA-6 trial investigated a proactive treatment switch for patients who developed ESR1 mutations (ESR1m) while on first-line therapy with an aromatase inhibitor (AI) and a CDK4/6 inhibitor. Rather than waiting for radiographic evidence of disease progression, researchers used ctDNA monitoring (Guardant360 assay) to detect resistance early.

The study randomized 315 patients who had detectable ESR1m but no clinical progression to either continue their current AI or switch to camizestrant (75 mg daily), a next-generation selective estrogen receptor degrader (ngSERD), while maintaining their CDK4/6 inhibitor.

Prolonging patient stability and survival

The updated primary endpoint data showed that the switch to camizestrant resulted in a median progression-free survival (PFS) of 16.8 months, compared to 9.2 months for those who remained on an AI. This 7.6-month absolute median improvement (HR 0.45) represents a substantial period of disease stability for the patient.

Crucially for long-term planning, the PFS2 (second progression-free survival) also favored the early switch, with a median of 25.7 months versus 19.1 months (HR 0.63). This demonstrates that the benefit of intervening early with camizestrant is sustained even after the first subsequent line of therapy.

Nursing priority: Symptom management and QoL

For frontline oncology nurses, the impact of a therapy on a patient's daily functioning is as critical as survival metrics. The SERENA-6 trial reported that camizestrant reduced the risk of deterioration in patient-reported cancer symptoms and functioning.

According to EORTC QLQ-C30 and BR23 assessments, patients in the camizestrant arm experienced:

• Lower risk of worsening global health status and QoL (HR 0.48).
• Reduced deterioration in physical and emotional functioning.
• Significant delays in the worsening of symptoms, including pain (HR 0.54), fatigue (HR 0.68), and shortness of breath/dyspnea (HR 0.41).

By proactively switching to a better-tolerated endocrine backbone before clinical failure occurs, clinicians can prevent the symptom surge often associated with disease flare-ups.

Delaying chemotherapy and ADCs

Another vital outcome for nursing care is the extension of chemotherapy/ADC-free survival. The median time before a patient required cytotoxic chemotherapy or an ADC was 22.6 months with camizestrant compared to 18.7 months with an AI (HR 0.64). This nearly four-month delay allows patients to avoid the more intensive side effect profiles — such as alopecia, myelosuppression, and severe nausea — often associated with these later-line therapies.

Monitoring molecular response

The trial also emphasized the clinical utility of liquid biopsies. A total of 51% of patients on camizestrant achieved total ctDNA clearance (becoming undetectable) by week 8 of treatment, whereas only 1.9% of patients in the AI group achieved clearance. Nurses may increasingly see these molecular markers used in practice, as ctDNA clearance was shown to be a strong predictor of overall survival benefit (HR 0.39).

Safety and tolerability

Camizestrant was well-tolerated, which is essential for maintaining adherence in the outpatient setting. No new safety signals were observed, and the discontinuation rate due to adverse events was 1% (n=2).

Reference

1. Bidard FC, Mayer E, Park YH, et al. First-line camizestrant for emergent ESR1 mutations in advanced breast cancer: Final progression-free survival 2 from the Phase III SERENA-6 trial. Presented at: 2026 ASCO Annual Meeting; May 29-June 2, 2026; Chicago, IL. LBA1007.